The role of pancreatic and duodenal homeobox 1 as a therapeutic target in pancreatic cancer

Expert Opinion on Therapeutic Targets

Volumn 18, Issue 11, 2014, Pages 1277-1283

  Fendrich, Volker ^a   Lauth, Matthias ^a  

^a PHILIPPS UNIVERSITY MARBURG   (Germany)

Author keywords

Pancreatic cancer; Pancreatic duodenal homeobox 1; Precursor lesions; Therapy

Indexed keywords

TRANSCRIPTION FACTOR PDX 1; ANTINEOPLASTIC AGENT; HOMEODOMAIN PROTEIN; PANCREATIC AND DUODENAL HOMEOBOX 1 PROTEIN; TRANSACTIVATOR PROTEIN;

APOPTOSIS; CANCER INHIBITION; CANCER SURVIVAL; CARCINOGENESIS; CELL INVASION; CELL PROLIFERATION; HUMAN; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; IN VIVO STUDY; NONHUMAN; OVERALL SURVIVAL; PANCREAS CANCER; PANCREAS INJURY; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN TARGETING; REVIEW; SURVIVAL TIME; UPREGULATION; ANIMAL; DRUG DESIGN; DRUG EFFECTS; METABOLISM; MOLECULARLY TARGETED THERAPY; PANCREATIC NEOPLASMS; PATHOLOGY; PHYSIOLOGY; SURVIVAL RATE;

ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; CELL PROLIFERATION; DRUG DESIGN; HOMEODOMAIN PROTEINS; HUMANS; MOLECULAR TARGETED THERAPY; PANCREATIC NEOPLASMS; SURVIVAL RATE; TRANS-ACTIVATORS;

EID: 84911494288     PISSN: 14728222     EISSN: 17447631     Source Type: Journal    
DOI: 10.1517/14728222.2014.945427     Document Type: Review

References (38)

1. Jemal A, Siegel R, Xu J, Ward E. Cancer statistics 2010. CA Cancer J Clin 2010;60:277-300
2. Wolfgang CL, Herman JM, Laheru DA, et al. Recent progress in pancreatic cancer. CA Cancer J Clin 2013;63:318-48
3. Vincent A, Herman J, Schulick R, et al. Pancreatic cancer. Lancet 2011;378:607-20
4. Feldmann G, Maitra A. Molecular genetics of pancreatic ductal adenocarcinomas and recent implications for translational efforts. J Mol Diagn 2008;10:111-22
5. Biankin AV, Waddell N, Kassahn KS, et al. Pancreatic cancer genomes reveal aberrations in axon guidance pathway genes. Nature 2012;494:399-405
6. Pérez-Mancera PA, Rust AG, van der Weyden L, et al. The deubiquitinase USP9X suppresses pancreatic ductal adenocarcinoma. Nature 2012;486:266-70
7. Yu M, Ting DT, Stott SL, et al. RNA sequencing of pancreatic circulating tumour cells implicates WNT signalling in metastasis. Nature 2012;487:510-13
8. Jones S, Hruban RH, Kamiyama M, et al. Exomic sequencing identifies PALB2 as a pancreatic cancer susceptibility gene. Science 2009;324:217
9. Jones S, Zhang X, Parsons DW, et al. Core signaling pathways in human pancreatic cancers revealed by global genomic analyses. Science 2008;321:1801-6
10. Yachida S, Jones S, Bozic I, et al. Distant metastasis occurs late during the genetic evolution of pancreatic cancer. Nature 2010;467:1114-17
11. Hingorani SR, Petricoin EF, Maitra A, et al. Preinvasive and invasive ductal pancreatic cancer and its early detection in the mouse. Cancer Cell 2003;4:437-50
12. Hingorani SR, Wang L, Multani AS, et al. Trp53R172H and KrasG12D cooperate to promote chromosomal instability and widely metastatic pancreatic ductal adenocarcinoma in mice. Cancer Cell 2005;7:469-83
13. Hezel AF, Kimmelman AC, Stanger BZ, et al. Genetics and biology of pancreatic ductal adenocarcinoma. Genes Dev 2006;20:1218-49
14. Guerra C, Collado M, Navas C, et al. Pancreatitis-induced inflammation contributes to pancreatic cancer by inhibiting oncogene-induced senescence. Cancer Cell 2011;19:728-39
15. Fendrich V, Chen NM, Neef M, et al. The angiotensin-I-converting enzyme inhibitor enalapril and aspirin delay progression of pancreatic intraepithelial neoplasia and cancer formation in a genetically engineered mouse model of pancreatic cancer. Gut 2010;59:630-7
16. Fendrich V. Chemoprevention of pancreatic cancer - one step closer. Langenbecks Arch Surg 2012;397:495-505
17. Rhim AD, Mirek ET, Aiello NM, et al. EMT and dissemination precede pancreatic tumor formation. Cell 2012;148:349-61
18. Burris HA III, Moore MJ, Andersen J, et al. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol 1997;15:2403-13
19. Moore MJ, Goldstein D, Hamm J, et al. Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 2007;25:1960-6
20. Conroy T, Desseigne F, Ychou M, et al. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med 2011;364:1817-25
21. Vaccaro V, Melisi D, Bria E, et al. Emerging pathways and future targets for the molecular therapy of pancreatic cancer. Expert Opin Ther Targets 2011;15:1183-96
22. Shih HP, Wang A, Sander M. Pancreas organogenesis: from lineage determination to morphogenesis. Annu Rev Cell Dev Biol 2013;29:81-105
23. Miller CP, McGhee RE, Habener JF. IDX-1: a new homeodomain transcription factor expressed in rat pancreatic islets and duodenum that transactivates the somatostatin gene. EMBO J 1994;13:1145-56
24. Peshavaria M, Gamer L, Henderson E, et al. XIHbox 8, an endoderm-specific Xenopus homeodomain protein, is closely related to a mammalian insulin gene transcription factor. Mol Endocrinol 1994;8:806-16
25. Offield MF, Jetton TL, Labosky PA, et al. PDX-1 is required for pancreatic outgrowth and differentiation of the rostral duodenum. Development 1996;122:983-95
26. Holland AM, Hale MA, Kagami H, et al. Experimental control of pancreatic development and maintenance. Proc Natl Acad Sci USA 2002;99:12236-41
27. Guz Y, Montminy MR, Stein R, et al. Expression of murine STF-1, a putative insulin gene transcription factor, in b cells of pancreas, duodenal epithelium and pancreatic exocrine and endocrine progenitors during ontogeny. Development 1995;121:149-61
28. Ahlgren U, Jonsson J, Jonsson L, et al. Beta-cell specific inactivation of the mouse Ipf1/Pdx1 gene results in loss of the beta-cell phenotype and maturity onset diabetes. Genes Dev 1998;12:1763-8
29. Cano DA, Hebrok M, Zenker M. Pancreatic development and disease. Gastroenterology 2007;132:745-62
30. Park JY, Hong SM, Klimstra DS, et al. Pdx1 expression in pancreatic precursor lesions and neoplasms. Appl Immunohistochem Mol Morphol 2011;19:444-9
31. Sharma A, Zangen DH, Reitz P, et al. The homeodomain protein IDX-1 increases after an early burst of proliferation during pancreatic regeneration. Diabetes 1999;48:507-13
32. Fendrich V, Esni F, Garay MV, et al. Hedgehog signaling is required for effective regeneration of exocrine pancreas. Gastroenterology 2008;135:621-31
33. Habbe N, Shi G, Meguid RA, et al. Spontaneous induction of murine pancreatic intraepithelial neoplasia (mPanIN) by acinar cell targeting of oncogenic Kras in adult mice. Proc Natl Acad Sci USA 2008;105:18913-18
34. Koizumi M, Doi R, Toyoda E, et al. Increased PDX-1 expression is associated with outcome in patients with pancreatic cancer. Surgery 2003;134:260-6
35. Wang XP, Li ZJ, Magnusson J, et al. Tissue microarray analyses of pancreatic duodenal homeobox-1 in human cancers. World J Surg 2005;29:334-8
36. Liu S, Ballian N, Belaguli NS, et al. PDX-1 acts as a potential molecular target for treatment of human pancreatic cancer. Pancreas 2008;37:210-20
37. Liu SH, Patel S, Gingras MC, et al. PDX-1: demonstration of oncogenic properties in pancreatic cancer. Cancer 2011;117:723-33
38. Liu SH, Rao DD, Nemunaitis J, et al. PDX-1 is a therapeutic target for pancreatic cancer, insulinoma and islet neoplasia using a novel RNA interference platform. PLoS One 2012;7:e40452